IP Library Granted Patent US 8,178,506
Granted Patent B2
US 8,178,506 · App. 12/345,780 · Granted May 15, 2012

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

Assignee: Regulus Therapeutics Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,178,506
App. No.
12/345,780
Granted
May 15, 2012
Kind
B2
Abstract

Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.

Claims (22)

1. A method of modulating the level of a precursor miRNA comprising:

contacting a cell with an oligomeric compound consisting of 15 to 30 monomeric subunits; wherein the oligomeric compound is complementary to the precursor miRNA and at least one monomeric subunit is a modified nucleoside or a nucleoside mimetic; and thereby modulating the level of the precursor miRNA.

2. The method of claim 1 wherein the contacting comprises inhibiting processing of the precursor miRNA.

3. The method of claim 1 wherein the level of the precursor miRNA is decreased.

4. The method of claim 1 wherein the oligomeric compound is complementary to a region flanking a Drosha cleavage site within the precursor miRNA.

5. The method of claim 1 wherein the precursor miRNA is a a pri-miRNA or a pre-miRNA.

6. The method of claim 5 wherein the oligomeric compound is complementary to a region of a pri-miRNA comprising a 5′ Drosha cleavage site.

7. The method of claim 5 wherein the oligomeric compound is complementary to a region of a pri-miRNA comprising a 3′ Drosha cleavage site.

8. The method of claim 1 wherein the oligomeric compound is complementary to a region comprising the miRNA.

9. The method of claim 1 wherein the oligomeric compound is complementary to a region comprising a loop structure.

10. The method of claim 1 wherein the level of a pri-miRNA is increased.

11. The method of claim 1 wherein the precursor miRNA comprises two or more miRNAs.

12. The method of claim 11 wherein the contacting comprises inhibiting the processing of two or more miRNAs.

13. The method of claim 11 wherein the precursor miRNA is a polycistronic precursor, and the polycistronic precursor is contacted with a first oligomeric compound complementary to a first region of the polycistronic precursor and a second oligomeric compound complementary to a second region of the polycistronic precursor.

14. The method of claim 1 wherein at least one monomeric subunit comprises at least one modified sugar moiety.

15. The method of claim 14 wherein the modified sugar moiety is chosen from 2′-F, 2′-O-methyl, 2′-O-methoxyethyl, and a bicyclic sugar moiety.

16. The method of claim 1 wherein the modified nucleoside or nucleoside mimetic comprises at least one modified internucleoside linkage.

17. The method of claim 16 wherein the modified internucleoside linkage is a phosphorothioate linkage.

18. The method of claim 1 wherein each monomeric subunit comprises a modified sugar moiety.

19. The method of claim 18 wherein the modified sugar moiety is 2′-O-methoxyethyl.

20. The method of claim 1 wherein the oligomeric compound consists of 17 to 25 monomeric subunits.

21. The method of claim 1 wherein the oligomeric compound is a single-stranded oligonucleotide.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded May 14, 2024
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT AND LENDER
To: REGULUS THERAPEUTICS INC.
Reel/Frame 067402/0782 →
SECURITY INTEREST Recorded Aug 8, 2018
From: REGULUS THERAPEUTICS INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT AND LENDER
Reel/Frame 046748/0561 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2010
From: ESAU, CHRISTINE; LOLLO, BRIDGET; BENNETT, C. FRANK; FREIER, SUSAN M.; GRIFFEY, RICHARD H.; BAKER, BRENDA F.; VICKERS, TIMOTHY A.; MARCUSSON, ERIC G.; KOLLER, ERICH; SWAYZE, ERIC E.; JAIN, RAVI; BHAT, BALKRISHEN; PERALTA, EIGEN R.
To: ISIS PHARMACEUTICALS, INC.
Reel/Frame 024361/0782 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2010
From: ISIS PHARMACEUTICALS, INC.
To: REGULUS THERAPEUTICS, LLC
Reel/Frame 024361/0870 →
CHANGE OF NAME Recorded May 10, 2010
From: REGULUS THERAPEUTICS, LLC
To: REGULUS THERAPEUTICS INC.
Reel/Frame 024362/0224 →
Continuity (6)
Division 10909125 · Jul 30, 2004
Provisional Application 60562417 · Apr 14, 2004
Provisional Application 60531596 · Dec 19, 2003
Provisional Application 60516303 · Oct 31, 2003
Provisional Application 60492056 · Jul 31, 2003
Related Publication 20090298174A1 · Dec 3, 2009